Primaquine is used to treat malaria, particularly to prevent the disease from recurring by killing parasites that hide in the liver. It's also used to treat a lung infection called pneumocystis pneumonia in people with weakened immune systems.[2] Primaquine is currently approved and in use across 7 indications[4].[1]
Primaquine is one of 186 small molecule programs targeting Glucosephosphate Dehydrogenase Deficiency. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
190 competitors in Obesity
Primaquine
NNC0487-0111
Cagrisema
Gemtesa
Zenagamtide
Berobenatide
Ribupatide
Efsubaglutide Alfa
Survodutide
Semaglutide or Tirzepatide
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
PRIMAQUINE
NDA NDA008316
Sources